Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|NSABP-B-51||NSABP||A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-40||NSABP||A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-R-04||NSABP||A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-33||NSABP||A Randomized; Placebo-Controlled; Double-Blind Trial Evaluating the Effect of Exemestane in Clinical Stage T1-3N0-1M0 Postmenopausal Breast Cancer Patients Completing at Least Five Years of Tamoxifen Therapy||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-52||NSABP||A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive; HER2-Positive; Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel; Carboplatin; Trastuzumab; and Pertuzumab (TCHP) With or Without Estrogen Deprivation||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-34||NSABP||A Clinical Trial Comparing Adjuvant Clodronate Therapy vs. Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy||Adult CIRB - Late Phase Emphasis||Completed|
|B-31 dbGAP||NSABP||Comparison of methods for development of predictive signatures for therapy selection||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-55||NSABP||A Randomised; Double-blind; Parallel group; Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-42||NSABP||A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-35||NSABP||A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy||Adult CIRB - Late Phase Emphasis||Completed|